

# CITATION REPORT

List of articles citing

p53, c-erbB-2 and the epidermal growth factor receptor  
in the benign and malignant prostate

DOI: 10.1016/s0022-5347(17)37287-7  
Journal of Urology, 1992, 147, 496-9.

**Source:** <https://exaly.com/paper-pdf/23051145/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
157	Chromosomal abnormalities and related events in prostate cancer. <b>1992</b> , 23, 368-80		106
156	Current and proposed biologic markers in prostate cancer. <b>1992</b> , 16H, 65-7		5
155	In situ hybridization for epidermal growth factor receptor (EGFR) external domain transcripts in prostatic adenocarcinoma. <b>1993</b> , 7, 188-95		19
154	Mutant p53 expression in prostate carcinoma. <i>Prostate</i> , <b>1993</b> , 22, 23-30	4.2	65
153	Expression of NEU/HER-2 oncoprotein (p185neu) in prostate tumors: an immunohistochemical study. <i>Prostate</i> , <b>1993</b> , 23, 329-36	4.2	32
152	Growth factors and their receptors as determinants in the proliferation and metastasis of human prostate cancer. <b>1993</b> , 12, 287-301		103
151	Rodent models for targeted oncogenesis of the prostate gland. <b>1993</b> , 12, 11-9		11
150	p53 expression and clinical outcome in prostate cancer. <b>1993</b> , 72, 778-81		65
149	Amplification and expression of the TGF-alpha, EGF receptor and c-myc genes in four human oesophageal squamous cell carcinoma lines. <b>1993</b> , 13, 303-12		14
148	Numerical chromosomal aberrations in prostate cancer: correlation with morphology and cell kinetics. <b>1993</b> , 422, 61-6		29
147	p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. <b>1993</b> , 85, 1657-69		386
146	Tumor suppressor genes in urologic tumors. <b>1993</b> , 42, 461-6; discussion 466-7		8
145	Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- and post-treatment specimens. <i>British Journal of Cancer</i> , <b>1993</b> , 68, 380-4	8.7	39
144	p53 expression in incidental prostatic cancer. <b>1993</b> , 305, 275-9		18
143	Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. <i>Journal of Urology</i> , <b>1993</b> , 150, 1427-33	2.5	136
142	Adenocarcinoma of the prostate. Part II: Tissue prognosticators. <b>1993</b> , 100, 256-69		30
141	New prognostic factors in prostatic carcinoma. <b>1993</b> , 24, 438-49		23

140	Familial clustering of breast and prostate cancers and risk of postmenopausal breast cancer. <b>1994</b> , 86, 1860-5		64
139	C-erbB-2 immunostaining: problems with interpretation. <b>1994</b> , 47, 816-22		75
138	Comparative analysis of epidermal growth factor receptor gene expression and protein product in benign, premalignant, and malignant prostate tissue. <i>Prostate</i> , <b>1994</b> , 25, 199-205	4.2	43
137	Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas. <i>Prostate</i> , <b>1994</b> , 25, 243-8	4.2	49
136	An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. <b>1994</b> , 172, 5-12		475
135	Tumorigenicity of SV40 T antigen immortalized human prostate epithelial cells: association with decreased epidermal growth factor receptor (EGFR) expression. <b>1994</b> , 58, 721-9		98
134	Prostatic carcinoma: a multivariate analysis of prognostic factors. <i>British Journal of Cancer</i> , <b>1994</b> , 69, 924-30	8.7	30
133	p53 gene mutations in human prostate cancers in Japan: different mutation spectra between Japan and western countries. <b>1994</b> , 85, 904-10		32
132	Abnormalities in p53 and DNA content in transitional cell carcinoma of the bladder. <b>1994</b> , 73, 522-5		19
131	Prognostic value of c-erbB-2 and epidermal growth factor receptor in stage A1 (T1a) prostatic adenocarcinoma. <b>1994</b> , 74, 214-20		45
130	Association of p53 immunoreactivity with high gleason tumor grade in prostatic adenocarcinoma. <b>1994</b> , 25, 92-7		58
129	Proto-oncogenes and tumor suppressor genes in human urological malignancies. <i>Journal of Urology</i> , <b>1994</b> , 151, 1479-97	2.5	57
128	Immunohistochemical detection of p53 protein in human prostatic cancer. <i>Journal of Urology</i> , <b>1994</b> , 152, 1297-301	2.5	60
127	p53 protein and c-erbB-2 protein (p185) expression in endometrial adenocarcinoma of endometrioid type. An immunohistochemical examination on paraffin sections. <b>1994</b> , 102, 76-9		28
126	Retinoblastoma and p53 genes as prognostic indicators in urological oncology. <b>1994</b> , 53, 1-5		8
125	Benigne Prostatahyperplasie (BPH) und Prostatitis. Eine histomorphologische und zellkinetische Analyse. <b>1995</b> , 26, 235-240		1
124	Neuroendocrine differentiation in prostatic carcinoma. Recent findings and new concepts. <i>Cancer</i> , <b>1995</b> , 75, 1850-1859	6.4	65
123	Measurement of c-erbB-2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoprotein. <b>1995</b> , 9, 151-65		23

122	Gene amplifications in advanced-stage human prostate cancer. <b>1995</b> , 22, 343-7		27
121	TP53 mutations in prostatic cancer. Analysis of pre- and post-treatment archival formalin-fixed tumour tissue. <b>1995</b> , 176, 299-308		15
120	p53 mutations occur in clinical, but not latent, human prostate carcinoma. <b>1995</b> , 86, 57-63		33
119	Genetic Alterations in Prostate Adenocarcinoma. <b>1995</b> , 4, 241-255		4
118	Immunohistochemical detection of oncogene proteins and neuroendocrine differentiation in different stages of prostate cancer. <b>1995</b> , 27, 229-32		17
117	Epidermal growth factor receptor expression by northern analysis and immunohistochemistry in benign and malignant prostatic tumours. <i>European Journal of Cancer</i> , <b>1995</b> , 31A, 1492-7	7.5	20
116	Molecular insights into altered cell cycle regulation and genitourinary malignancy. <b>1995</b> , 1, 3-17		7
115	The prognostic significance of tumor-associated markers p53, HER-2/neu, c-myc, v-H-ras, PCNA and EGFR of local and distant recurrence in localized human prostatic adenocarcinoma. <b>1995</b> , 1, 144-52		6
114	OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. <b>1995</b> , 45, 81-6		178
113	Immunoreactive p53 protein in high-grade prostatic intraepithelial neoplasia. <i>Pathology Research and Practice</i> , <b>1995</b> , 191, 881-7	3.4	10
112	Review of Peptide Growth Factors in Benign Prostatic Hyperplasia and Urological Malignancy. <i>Journal of Urology</i> , <b>1995</b> , 153, 1085-1096	2.5	111
111	Cathepsin D and Epidermal Growth Factor Receptor Immunohistochemistry does not Predict Recurrence of Prostate Cancer in Patients Undergoing Radical Prostatectomy. <i>Journal of Urology</i> , <b>1996</b> , 155, 982-985	2.5	20
110	The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker?. <b>1996</b> , 48, 971-9		47
109	Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. <b>1996</b> , 27, 573-80		27
108	Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue. <b>1996</b> , 27, 688-94		54
107	The effects of dihydrotestosterone on the expression of p185(erbB-2) and c-erbB-2 mRNA in the prostatic cell line LNCaP. <b>1996</b> , 59, 441-7		13
106	Biomarker expression in prostatic intraepithelial neoplasia. <b>1996</b> , 30, 153-66		45
105	p53 immunoreactivity as prognostic marker for cancer-specific survival in prostate cancer. <b>1996</b> , 30, 65-72		16

104	Action, localization and structure-function relationship of growth factors and their receptors in the prostate. <b>1996</b> , 5, 73-105		6
103	Loss of heterozygosity on chromosomes 10 and 17 in clinically localized prostate carcinoma. <i>Prostate</i> , <b>1996</b> , 28, 275-81	4.2	25
102	Molecular biology of prostatic intraepithelial neoplasia. <i>Prostate</i> , <b>1996</b> , 29, 117-34	4.2	148
101	bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. <i>British Journal of Cancer</i> , <b>1996</b> , 74, 1258-62	8.7	110
100	Genetic basis and clonal evolution of human prostate cancer. <i>Advances in Cancer Research</i> , <b>1996</b> , 68, 225-55	5.5	45
99	Involvement of transforming growth factor alpha (TGFalpha) and epidermal growth factor receptor (EGFR) in sex hormone-induced prostatic dysplasia and the growth of an androgen-independent transplantable carcinoma of the prostate. <b>1996</b> , 17, 2571-9		20
98	Loss of response to epidermal growth factor and retinoic acid accompanies the transformation of human prostatic epithelial cells to tumorigenicity with v-Ki-ras. <b>1997</b> , 18, 1643-50		6
97	Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy. <b>1997</b> , 50, 384-8		26
96	Das Wachstumssuppressorprotein p53, seine zellulären Partner und das Prostatakarzinom. <b>1997</b> , 28, 371-376		
95	Oncogenes and tumor suppressor genes in prostate cancer: a review. <b>1997</b> , 3, 41-6		14
94	Minimal criteria for the diagnosis of prostate cancer on needle biopsy. <b>1997</b> , 1, 104-29		15
93	The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. <b>1997</b> , 79, 190-5		52
92	Expression of p21 and mutant p53 gene products in residual prostatic tumor cells after radical radiotherapy. <i>Prostate</i> , <b>1997</b> , 32, 99-105	4.2	5
91	Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. <i>Cancer</i> , <b>1997</b> , 79, 2162-70	6.4	97
90	Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells. <i>British Journal of Cancer</i> , <b>1998</b> , 77, 855-61	8.7	100
89	Chromosome 7 abnormalities in prostate cancer detected by dual-color fluorescence in situ hybridization. <b>1998</b> , 107, 51-60		33
88	Over-expression of epidermal growth factor receptor and c-erbB2/neu but not of int-2 genes in benign prostatic hyperplasia by means of semi-quantitative PCR. <b>1998</b> , 76, 464-7		14
87	Androgen-independent basal cell re-epithelialization, c-erbB-2 mRNA expression and androgen-dependent EGFR mRNA expression in benign prostatic hyperplasia explant cultures treated with finasteride. <b>1998</b> , 76, 519-22		7

86	Cell kinetics of prostate exocrine and neuroendocrine epithelium and their differential interrelationship: New perspectives. <i>Prostate</i> , <b>1998</b> , 36, 62-73	4.2	37
85	Comparative analysis of epidermal growth factor receptor mRNA levels in normal, benign hyperplastic and carcinomatous prostate. <i>Cancer Letters</i> , <b>1998</b> , 134, 177-80	9.9	19
84	The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy. <i>European Journal of Cancer</i> , <b>1998</b> , 34, 679-86	7.5	36
83	Alteration of the p53 Tumor Suppressor Gene in Prostate Cancer: Analytical Approaches and Clinical Implications. <b>1998</b> , 21, 113-122		0
82	Apoptosis regulating genes in prostate cancer (review). <b>1998</b> , 5, 553-7		20
81	Evaluation of biomarker modulation by fenretinide in prostate cancer patients. <b>1999</b> , 35, 429-38		25
80	Gains of the relative genomic content of erbB-1 and erbB-2 in prostate carcinoma and their association with metastasis. <b>1999</b> , 14, 367-71		8
79	Molecular genetics and epidemiology of prostate carcinoma. <b>1999</b> , 20, 22-45		130
78	A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. <b>1999</b> , 5, 280-5		799
77	Target antigens for prostate cancer immunotherapy. <b>1999</b> , 18, 437-49		25
76	Analysis of protooncogene c-erbB-2 in benign and malignant human prostate. <b>1999</b> , 31, 61-73		11
75	The need for microdissectional tumor cell preparation during the molecular genetic analysis of prostate cancer. <b>1999</b> , 17, 115-22		3
74	Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastatic prostate cancer. <b>1999</b> , 84, 421-5		56
73	Two different forms of p53 localized differently within cells of urogenital tumours. <i>Cancer Letters</i> , <b>1999</b> , 144, 55-64	9.9	10
72	Chapter 8 Molecular progression of prostate cancer. <b>1999</b> , 3, 155-187		
71	Identification of a superimmunoglobulin gene family member overexpressed in benign prostatic hyperplasia. <i>Prostate</i> , <b>2000</b> , 42, 230-8	4.2	6
70	Chemotherapy for hormone-refractory prostate cancer: beauty is in the eye of the beholder. <i>Prostate</i> , <b>2000</b> , 45, 184-93	4.2	25
69	Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. <i>British Journal of Cancer</i> , <b>2000</b> , 82, 186-94	8.7	134

68	Breast and prostate cancer. <b>2000</b> , 15, 110-7		4
67	Overexpression of p53 in prostate carcinoma is associated with improved overall survival but not predictive of response to radiotherapy. <b>2000</b> , 17, 761-9		3
66	Growth factors and their receptors: new targets for prostate cancer therapy. <b>2001</b> , 58, 114-22		94
65	Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. <i>Journal of Urology</i> , <b>2001</b> , 166, 1514-9	2.5	101
64	Androgen receptor signaling in androgen-refractory prostate cancer. <b>2001</b> , 93, 1687-97		445
63	Androgen receptor signalling in the prostate. <i>BJU International</i> , <b>2000</b> , 86, 1001-13	5.6	47
62	Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis. <i>BJU International</i> , <b>2001</b> , 88 Suppl 2, 35-42; discussion 49-50	5.6	48
61	HER-Kinase-Directed Therapy of Prostate Cancer. <b>2001</b> , 3, 53-58		2
60	HER2 protein expression and gene amplification in androgen-independent prostate cancer. <b>2001</b> , 116, 234-9		61
59	The role of receptors in prostate cancer. <b>2000</b> , 35, 101-60		1
58	17 Expression and gene copy number alterations of her-2/neu (ERBB2) gene in prostate cancer. <b>2002</b> , 2, 449-456		
57	Efficacy of vaccination with plasmid DNA encoding for HER2/neu or HER2/neu-eGFP fusion protein against prostate cancer in rats. <i>International Immunopharmacology</i> , <b>2002</b> , 2, 783-96	5.8	14
56	The Molecular Biology of Prostate Cancer. 141-159		1
55	. <b>2002</b> ,		
54	Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology. <i>Cancer</i> , <b>2002</b> , 95, 1650-5	6.4	45
53	Repression of androgen receptor mediated transcription by the ErbB-3 binding protein, Ebp1. <i>Oncogene</i> , <b>2002</b> , 21, 5609-18	9.2	64
52	Epithelial cell differentiation in the human prostate epithelium: implications for the pathogenesis and therapy of prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2003</b> , 46 Suppl, S3-10	7	53
51	ErbB receptors: possible therapeutic targets in prostate cancer?. <i>BJU International</i> , <b>2003</b> , 92, 890-5	5.6	26

50	Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. <i>Clinical Prostate Cancer</i> , <b>2003</b> , 2, 50-7		49
49	Prostate cancer: advances in immunotherapy. <i>BioDrugs</i> , <b>2003</b> , 17, 131-8	7.9	11
48	Advances in immunotherapy for prostate cancer. <i>Advances in Cancer Research</i> , <b>2003</b> , 87, 159-194	5.9	6
47	Her-2/Neu Receptor in Prostate Cancer Development and Progression to Androgen Independence. <i>Tumori</i> , <b>2004</b> , 90, 163-170	1.7	35
46	The role of HER2/neu, BCL2, p53 genes and proliferating cell nuclear protein as molecular prognostic parameters in localized prostate carcinoma. <i>Sao Paulo Medical Journal</i> , <b>2004</b> , 122, 124-7	1.6	7
45	Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. <i>British Journal of Cancer</i> , <b>2004</b> , 90, 449-54	8.7	127
44	Molecular biology of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , <b>2004</b> , 7, 6-20	6.2	35
43	Transgenic mouse with human mutant p53 expression in the prostate epithelium. <i>Prostate</i> , <b>2004</b> , 61, 26-34	4.2	15
42	Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin alpha-conjugate. <i>Cancer Letters</i> , <b>2004</b> , 205, 161-71	9.9	22
41	HER2 and COX2 expression in human prostate cancer. <i>European Journal of Cancer</i> , <b>2004</b> , 40, 50-5	7.5	66
40	Association of HER-2 polymorphism with Japanese sporadic prostate cancer susceptibility. <i>Prostate</i> , <b>2005</b> , 62, 49-53	4.2	7
39	The Molecular Biology of Prostate Cancer. <b>2005</b> , 3-16		
38	Molecular markers of prostate cancer outcome. <i>European Journal of Cancer</i> , <b>2005</b> , 41, 858-87	7.5	153
37	Genetic alterations in prostate cancer. <i>Clinical Prostate Cancer</i> , <b>2005</b> , 3, 220-9		1
36	Tratamiento de adenocarcinoma prostático localizado en paciente con trasplante renal mediante Ultrasonido de Alta Intensidad. <i>Actas Urológicas Españolas</i> , <b>2005</b> , 29, 64-69	0.7	
35	Cancer of the Prostate: Molecular Genetics. <b>2006</b> ,		
34	Immunotherapy for prostate cancer. <i>Current Pharmaceutical Design</i> , <b>2006</b> , 12, 807-17	3.3	15
33	ErbB1/ErbB4 nuclear and cytoplasmic overexpression, ethnicity and predicted outcome in prostate cancer. <i>Targeted Oncology</i> , <b>2008</b> , 3, 13-17	5	2



32	Prostate Cancer. <b>2008</b> ,		3
31	Molecular markers and death from prostate cancer. <i>Annals of Internal Medicine</i> , <b>2009</b> , 150, 595-603	8	38
30	Molecular Oncogenesis of Prostate Adenocarcinoma: Role of the Human Epidermal Growth Factor Receptor 2 (HER-2/neu). <i>Tumori</i> , <b>2010</b> , 96, 645-649	1.7	16
29	Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 1553-60	12.9	113
28	The Scientific Basis of Urology. <b>2010</b> ,		9
27	HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 16392-7	11.5	47
26	A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53. <i>Oncogene</i> , <b>2012</b> , 31, 322-32	9.2	45
25	LNCaP prostate cancer cells with autocrine interleukin-6 expression are resistant to IL-6-induced neuroendocrine differentiation due to increased expression of suppressors of cytokine signaling. <i>Prostate</i> , <b>2012</b> , 72, 1306-16	4.2	23
24	Biomarkers in Oncology. <b>2013</b> ,		1
23	ErbB receptor tyrosine kinase family expression levels in urothelial bladder carcinoma. <i>Pathology Research and Practice</i> , <b>2013</b> , 209, 99-104	3.4	9
22	HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology. <i>Clinical Investigation</i> , <b>2014</b> , 4, 705-728		8
21	Nonneoplastic Diseases of the Prostate. <b>2020</b> , 358-414.e13		
20	Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase. <i>Cancer Treatment and Research</i> , <b>1994</b> , 71, 161-91	3.5	20
19	Transgenic Mouse Models of Prostate Cancer. <b>2001</b> , 401-425		3
18	Hormone Therapy for Prostate Cancer. <b>2003</b> , 237-248		1
17	Molecular Dissection of the Prostate Cancer Genome. <b>2003</b> , 25-40		2
16	HER-2/NEU EXPRESSION IN PROSTATE CANCER:. <i>Journal of Urology</i> , <b>2001</b> , 1514-1519	2.5	5
15	Monoclonal Antibodies for Imaging and Therapy of Prostate Cancer. <b>2000</b> , 305-315		

- 14 Molecular Genetics and Markers of Progression. **2000**, 47-70
- 13 Type I Family Growth Factor Receptors and Their Ligands in Prostate Cancer. **2000**, 277-291
- 12 Pathophysiologie. **2000**, 63-136
- 11 Opportunities for Targeted Molecular Therapy for Prostate Cancer. **2004**, 631-652
- 10 Molekulare Mechanismen von Veränderungen und Erkrankungen der Prostata. **2004**, 296-343
- 9 Prostate Cancer. **2010**, 386-402
- 8 Molecular Markers of Prostate Cancer Outcome. **2013**, 189-247
- 7 Biochemistry of Prostate Cancer. **1994**, 145-161
- 6 Hormonal Influences on the Prostate Gland. **1995**, 13-21
- 5 Prostatic Growth Factors, Cancer, and Steroid Hormone Activity. **1996**, 415-444
- 4 Total androgen blockade for prostate cancer: the end does not justify the means. *Cancer Treatment and Research*, **1996**, 88, 201-10 3·5
- 3 Pathologische Anatomie maligner Tumoren der Prostata. **1999**, 3-44
- 2 Role of PI3K/Akt and PTEN in the Growth and Progression of Prostate Cancer. **2008**, 291-308
- 1 Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. *American Journal of Pathology*, **1994**, 145, 287-93 5·8 41